Open AccessAdoption of Serogroup B Meningococcal Vaccine Recommendations
Author(s) -
Allison Kempe,
Mandy A. Allison,
Jessica R. MacNeil,
Sean T. O’Leary,
Lori A. Crane,
Brenda L. Beaty,
Laura P. Hurley,
Michaela Brtnikova,
Megan C. Lindley,
Alison P. Albert
Publication year - 2018
Publication title -
pediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.611
H-Index - 345
eISSN - 1098-4275
pISSN - 0031-4005
DOI - 10.1542/peds.2018-0344
Subject(s) - medicine , meningococcal vaccine , vaccination , meningococcal disease , outbreak , advisory committee , family medicine , confidence interval , immunization , incidence (geometry) , pediatrics , neisseria meningitidis , immunology , virology , physics , public administration , antigen , biology , bacteria , political science , optics , genetics
: media-1vid110.1542/5799875076001PEDS-VA_2018-0344 Video Abstract BACKGROUND AND OBJECTIVES: In 2015, the Advisory Committee on Immunization Practices recommended that 16- to 23-year-olds may be vaccinated with the serogroup B meningococcal (MenB) vaccine on the basis of individual clinical decision-making (Category B). We assessed the following among US pediatricians and family physicians (FPs): (1) practices regarding MenB vaccine delivery, (2) factors influencing a decision to recommend the MenB vaccine, and (3) factors associated with discussing the MenB vaccine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom